Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders

• Published in: Journal of molecular biology 2024-02, Vol.436 (4), p.168446, Article 168446
• Main Authors: Thomas, Sanya, Pak, Jensen, Doss-Gollin, Simon, Ryff, Kevin, Beijnen, Elisabeth, Pedersen, Gabriel K., Christensen, Dennis, Levy, Ofer, van Haren, Simon D.
• Format: Article
• Language: English
• Subjects: Adjuvant; Adjuvants, Immunologic - pharmacology; Adolescent; Adult; CD4; CD8; Cross-Priming - drug effects; Cytokines - metabolism; Dendritic cell; Dendritic Cells - immunology; Humans; Infant, Newborn; Newborn; Older adult; Th1 Cells - immunology; Toll-Like Receptor 9; Vaccine; Vaccine Development; Viral Vaccines - immunology; Young Adult
• ISSN: 0022-2836; 1089-8638; 1089-8638
• DOI: 10.1016/j.jmb.2024.168446

[Display omitted] •Human in vitro modeling identifies adjuvants that activate CD4+ and CD8+ T cells.•Several adjuvant combinations induced varying immunophenotypic responses.•TLR7/8-stimulating adjuvants differed in their propensity to induce T cells.•CpG + 2,3-cGAMP was most potent in inducing cDC1-like dendritic cells.•CpG + 2,3-cGAMP is a promising adjuvant candidate for vaccine development tailored towards vulnerable populations. Adjuvants are vaccine components that can boost the type, magnitude, breadth, and durability of an immune response. We have previously demonstrated that certain adjuvant combinations can act synergistically to enhance and shape immunogenicity including promotion of Th1 and cytotoxic T-cell development. These combinations also promoted protective immunity in vulnerable populations such as newborns. In this study, we employed combined antigen-specific human in vitro models to identify adjuvant combinations that could synergistically promote the expansion of vaccine-specific CD4+ cells, induce cross-presentation on MHC class I, resulting in antigen-specific activation of CD8+ cells, and direct the balance of immune response to favor the production of Th1-promoting cytokines. A screen of 78 adjuvant combinations identified several T cell-potentiating adjuvant combinations. Remarkably, a combination of TLR9 and STING agonists (CpG + 2,3-cGAMP) promoted influenza-specific CD4+ and CD8+ T cell activation and selectively favored production of Th1-polarizing cytokines TNF and IL-12p70 over co-regulated cytokines IL-6 and IL-12p40, respectively. Phenotypic reprogramming towards cDC1-type dendritic cells by CpG + 2,3-cGAMP was also observed. Finally, we characterized the molecular mechanism of this adjuvant combination including the ability of 2,3-cGAMP to enhance DC expression of TLR9 and the dependency of antigen-presenting cell activation on the Sec22b protein important to endoplasmic reticulum-Golgi vesicle trafficking. The identification of the adjuvant combination CpG + 2,3-cGAMP may therefore prove key to the future development of vaccines against respiratory viral infections tailored for the functionally distinct immune systems of vulnerable populations such as older adults and newborns.